Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
DNLI Analyst Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
DNLI Stock 12 Month Forecast
Average Price Target
$31.00
▲(70.70% Upside)
| Highest Price Target$37.00 | Average Price Target$31.00 | Lowest Price Target$26.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Wedbush
$31→$30
Buy
65.20%
Upside
Reiterated
12/11/25
William Blair
―
Buy
―
Reiterated
12/05/25
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy RatingWe believe Denali is well positioned with line-of-sight to an underappreciated tivi launch, and that the company stands to benefit from strong commercial synergies with for its follow-on product in DNL126 for Sanfilippo syndrome type A. There have been some setbacks with a priority review voucher now not expected or included in financial guidance if tivi is approved (about $150 million in the resale market) and the Pompe clinical programs being placed on FDA clinical hold (the company has responded to this, triggering a 30-day response window).
Stifel Nicolaus
$37
Buy
103.74%
Upside
Reiterated
12/05/25
Bank of America Securities
$26→$29
Buy
59.69%
Upside
Reiterated
12/04/25
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Cytokinetics (NASDAQ: CYTK) and Denali Therapeutics (NASDAQ: DNLI)We think 2026 will be a transformational year for DNLI as they transition to becoming a commercial organization and remain encouraged by the breadth of the pipeline with potential to expand into additional indications. We reiterate our Buy with new $29 PO (prev. $26).
BTIG
$32
Buy
76.21%
Upside
Reiterated
12/04/25
H.C. Wainwright
$32
Buy
76.21%
Upside
Reiterated
12/03/25
B. Riley Securities
$30
Buy
65.20%
Upside
Reiterated
12/01/25
Oppenheimer
$35
Buy
92.73%
Upside
Reiterated
11/10/25
TD Cowen
―
Buy
―
Reiterated
11/06/25
Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy RatingWe remain optimistic for approval of '310 after the recent PDUFA date extension, and note the company could have 2 products on the mkt over the next few yrs after AA alignment for '126 in MPS IIIA. Denali also has several P.C. TV programs near the clinic. We see DNLI shares as undervalued for the potential of the TV platform.
J.P. Morgan
$26
Buy
43.17%
Upside
Reiterated
11/03/25
Cantor Fitzgerald
―
Buy
―
Reiterated
09/08/25
Morgan Stanley
$33→$30
Buy
65.20%
Upside
Reiterated
08/18/25
Leerink Partners
$40
Buy
120.26%
Upside
Reiterated
08/13/25
Robert W. Baird
$30→$29
Buy
59.69%
Upside
Reiterated
05/08/25
Deutsche Bank
$31
Buy
70.70%
Upside
Initiated
02/11/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wedbush
$31→$30
Buy
65.20%
Upside
Reiterated
12/11/25
William Blair
―
Buy
―
Reiterated
12/05/25
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy RatingWe believe Denali is well positioned with line-of-sight to an underappreciated tivi launch, and that the company stands to benefit from strong commercial synergies with for its follow-on product in DNL126 for Sanfilippo syndrome type A. There have been some setbacks with a priority review voucher now not expected or included in financial guidance if tivi is approved (about $150 million in the resale market) and the Pompe clinical programs being placed on FDA clinical hold (the company has responded to this, triggering a 30-day response window).
Stifel Nicolaus
$37
Buy
103.74%
Upside
Reiterated
12/05/25
Bank of America Securities
$26→$29
Buy
59.69%
Upside
Reiterated
12/04/25
Analysts Conflicted on These Healthcare Names: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Cytokinetics (NASDAQ: CYTK) and Denali Therapeutics (NASDAQ: DNLI)We think 2026 will be a transformational year for DNLI as they transition to becoming a commercial organization and remain encouraged by the breadth of the pipeline with potential to expand into additional indications. We reiterate our Buy with new $29 PO (prev. $26).
BTIG
$32
Buy
76.21%
Upside
Reiterated
12/04/25
H.C. Wainwright
$32
Buy
76.21%
Upside
Reiterated
12/03/25
B. Riley Securities
$30
Buy
65.20%
Upside
Reiterated
12/01/25
Oppenheimer
$35
Buy
92.73%
Upside
Reiterated
11/10/25
TD Cowen
―
Buy
―
Reiterated
11/06/25
Denali Therapeutics: Promising Pipeline and Strategic Progress Justify Buy RatingWe remain optimistic for approval of '310 after the recent PDUFA date extension, and note the company could have 2 products on the mkt over the next few yrs after AA alignment for '126 in MPS IIIA. Denali also has several P.C. TV programs near the clinic. We see DNLI shares as undervalued for the potential of the TV platform.
J.P. Morgan
$26
Buy
43.17%
Upside
Reiterated
11/03/25
Cantor Fitzgerald
―
Buy
―
Reiterated
09/08/25
Morgan Stanley
$33→$30
Buy
65.20%
Upside
Reiterated
08/18/25
Leerink Partners
$40
Buy
120.26%
Upside
Reiterated
08/13/25
Robert W. Baird
$30→$29
Buy
59.69%
Upside
Reiterated
05/08/25
Deutsche Bank
$31
Buy
70.70%
Upside
Initiated
02/11/25
Best Analysts Covering Denali Therapeutics
1 Month
xxx
Success Rate
12/15 ratings generated profit
Average Return
+9.57%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +9.57% per trade.
3 Months
xxx
Success Rate
10/18 ratings generated profit
Average Return
+14.88%
reiterated a xxx
rating 20 hours ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +14.88% per trade.
1 Year
Success Rate
9/15 ratings generated profit
Average Return
+7.85%
reiterated a buy rating 9 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +7.85% per trade.
2 Years
xxx
Success Rate
9/15 ratings generated profit
Average Return
+5.31%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +5.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
DNLI Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
8
8
12
13
17
Buy
3
4
5
6
7
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
12
17
19
24
Each month's total comprises the sum of three months' worth of ratings.
DNLI Financial Forecast
DNLI Stock Forecast FAQ
What is DNLI’s average 12-month price target, according to analysts?
Based on analyst ratings, Denali Therapeutics’s 12-month average price target is 31.00.
What is DNLI’s upside potential, based on the analysts’ average price target?
Denali Therapeutics has 70.70% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is DNLI a Buy, Sell or Hold?
Denali Therapeutics has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is Denali Therapeutics’s price target?
The average price target for Denali Therapeutics is 31.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $37.00 ,the lowest forecast is $26.00. The average price target represents 70.70% Increase from the current price of $18.16.
The highest analyst price target is $37.00 ,the lowest forecast is $26.00. The average price target represents 70.70% Increase from the current price of $18.16.
What do analysts say about Denali Therapeutics?
Denali Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of DNLI?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.